Tourmaline Bio (TRML) Competitors $16.77 +0.59 (+3.61%) Closing price 07/3/2025 03:43 PM EasternExtended Trading$16.82 +0.04 (+0.24%) As of 07/3/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRML vs. TARS, BEAM, CNTA, ARQT, ADPT, IMCR, SPRY, EWTX, SDGR, and BHVNShould you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Schrodinger (SDGR), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Tourmaline Bio vs. Its Competitors Tarsus Pharmaceuticals Beam Therapeutics Centessa Pharmaceuticals Arcutis Biotherapeutics Adaptive Biotechnologies Immunocore ARS Pharmaceuticals Edgewise Therapeutics Schrodinger Biohaven Tarsus Pharmaceuticals (NASDAQ:TARS) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Do analysts recommend TARS or TRML? Tarsus Pharmaceuticals presently has a consensus target price of $66.67, indicating a potential upside of 62.28%. Tourmaline Bio has a consensus target price of $49.33, indicating a potential upside of 194.09%. Given Tourmaline Bio's higher possible upside, analysts plainly believe Tourmaline Bio is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in TARS or TRML? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 13.0% of Tourmaline Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer TARS or TRML? In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 2 mentions for Tarsus Pharmaceuticals and 1 mentions for Tourmaline Bio. Tarsus Pharmaceuticals' average media sentiment score of 1.23 beat Tourmaline Bio's score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tourmaline Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, TARS or TRML? Tarsus Pharmaceuticals has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Which has higher valuation & earnings, TARS or TRML? Tourmaline Bio has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M9.43-$115.55M-$2.73-15.05Tourmaline BioN/AN/A-$73.21M-$3.21-5.23 Is TARS or TRML more profitable? Tourmaline Bio has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Tourmaline Bio's return on equity of -26.75% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-44.91% -39.72% -25.74% Tourmaline Bio N/A -26.75%-26.11% SummaryTourmaline Bio beats Tarsus Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRML vs. The Competition Export to ExcelMetricTourmaline BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$421.76M$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.03%P/E Ratio-5.238.9827.5220.22Price / SalesN/A682.84421.02118.64Price / CashN/A158.5936.8958.07Price / Book1.434.588.045.67Net Income-$73.21M$31.34M$3.18B$249.13M7 Day Performance1.42%3.25%2.90%3.28%1 Month Performance-11.20%7.08%3.70%5.55%1 Year Performance33.88%0.17%36.15%21.12% Tourmaline Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRMLTourmaline Bio2.1424 of 5 stars$16.78+3.6%$49.33+194.1%+30.7%$421.76MN/A-5.2344TARSTarsus Pharmaceuticals2.2421 of 5 stars$40.60-0.1%$66.67+64.2%+42.0%$1.71B$182.95M-14.8750Positive NewsBEAMBeam Therapeutics2.7082 of 5 stars$16.71-0.3%$48.75+191.7%-14.7%$1.69B$63.52M-3.62510CNTACentessa Pharmaceuticals3.0445 of 5 stars$13.00+4.6%$27.89+114.5%+67.1%$1.66B$6.85M-7.18200ARQTArcutis Biotherapeutics2.0664 of 5 stars$14.40+4.2%$18.80+30.6%+42.9%$1.65B$212.82M-13.85150Positive NewsADPTAdaptive Biotechnologies3.3343 of 5 stars$10.56+1.7%$10.57+0.1%+253.3%$1.58B$178.96M-11.00790News CoverageGap UpIMCRImmunocore2.3758 of 5 stars$31.12-0.7%$58.89+89.2%-8.4%$1.57B$310.20M-72.37320SPRYARS Pharmaceuticals3.2498 of 5 stars$16.57+4.9%$31.00+87.1%+81.4%$1.55B$89.15M-103.5690Insider TradeEWTXEdgewise Therapeutics2.4951 of 5 stars$14.18-0.8%$39.78+180.5%-29.1%$1.50BN/A-9.1560News CoverageAnalyst RevisionSDGRSchrodinger2.7999 of 5 stars$20.35-0.5%$32.80+61.2%+4.3%$1.50B$207.54M-7.74790Analyst ForecastBHVNBiohaven3.4144 of 5 stars$14.44-0.2%$58.46+305.0%-56.7%$1.48BN/A-1.54239 Related Companies and Tools Related Companies Tarsus Pharmaceuticals Alternatives Beam Therapeutics Alternatives Centessa Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives Adaptive Biotechnologies Alternatives Immunocore Alternatives ARS Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Schrodinger Alternatives Biohaven Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRML) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRML Stock Alerts